TrialDiabetes, obesity & metabolism2021

A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.

Masaru Kitazawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.